Isotechnika Pharma Receives National Research Council IRAP Funding for NICAM Program

EDMONTON, Canada, March 4, 2010 - Isotechnika Pharma Inc. (TSX: ISA) today announced that it has received
funding approval from the National Research Council's Industrial Research
Assistance Program (IRAP) for its Non-Immunosuppressive Cyclosporin Analog
Molecules (NICAM) program. The grant of CDN$237,069 will support the
development progress of the NICAM program which is part of an emerging
therapeutic field that targets large and growing markets.

"Scientific research continues to validate cyclophilins as key
disease-modifying targets in the treatment of a wide range of indications
from myocardial infarction and virology to central nervous system disorders.
Our NICAM candidates have demonstrated potent inhibition of cyclophilins
without the immunosuppressive impacts typical of cyclosporine A," said
Dr. Launa Aspeslet, COO of Isotechnika Pharma. "This funding is an external
validation of our NICAM program awarded through a peer-reviewed process.
Research shows that cyclophilin inhibitors have neuroprotective effects
which open broad therapeutic areas of completely unmet medical need to
Isotechnika such as stroke, Alzheimer's, Parkinson's and Lou Gehrig's
disease."

Although cyclophilins are known molecular targets for a wide range of
indications, Isotechnika will use the funding from IRAP to support the
identification and selection of lead candidates for neuroprotection at this
time. The Company intends to pursue co-development or licensing partnerships
to support the development of the NICAM program.

About Isotechnika Pharma

————————

Edmonton-based Isotechnika Pharma Inc. is a biopharmaceutical company
focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed US$4 billion annually in
sales for calcineurin inhibitors such as voclosporin by 2011.

Voclosporin, Isotechnika Pharma's lead drug candidate, is a next
generation calcineurin inhibitor. It has completed a Phase 2b study for the
prevention of kidney rejection following transplantation and a Phase 3
European/Canadian trial for the treatment of moderate to severe psoriasis.
Our partner, Lux Biosciences, has filed dossiers for approval of voclosporin
in the U.S. and in Europe for the treatment of non-infectious uveitis. In the
U.S., Lux has been granted Fast Track designation. Lux Biosciences has also
conducted a Phase 1 trial using their proprietary voclosporin ophthalmic
solution (LX214) as a candidate for dry eye syndrome.

Isotechnika Pharma Inc. is a publicly traded company on the Toronto
Stock Exchange under the symbol "ISA". More information on Isotechnika
Pharma can be found at www.isotechnika.com or www.SEDAR.com.

Forward-Looking Statements

————————–

This News Release contains forward-looking statements which may not be
based on historical fact. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause actual results,
events or developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Such risks and uncertainties include, among others, the Company's
belief as to the potential of its products, its ability to protect its
intellectual property rights, securing and maintaining corporate alliances
and partnerships, the need for additional capital and the effect of capital
market conditions and other factors on capital availability, the ability to
economically manufacture its products, the potential of its products, the
success and timely completion of clinical studies and trials, and the
Company's and its partners' ability to successfully obtain regulatory
approvals and commercialize voclosporin. Investors should consult the
Company's quarterly and annual filings for additional information on risks
and uncertainties relating to the forward-looking statements. These factors
should be considered carefully and readers are cautioned not to place undue
reliance on such forward-looking statements.

For further information: Dr. Robert Foster, President & CEO, Isotechnika
Pharma Inc., +1-780-487-1600 ext. 247, +1-780-484-4105 (fax),
rfoster@isotechnika.com; Dr. Launa J Aspeslet, Chief Operating Officer,
Isotechnika Pharma Inc., +1-780-487-1600 ext. 225, +1-780-484-4105 (fax),
laspeslet@isotechnika.com

For further information: Dr. Robert Foster, President & CEO, Isotechnika Pharma Inc., +1-780-487-1600 ext. 247, +1-780-484-4105 (fax), rfoster at isotechnika.com; Dr. Launa J Aspeslet, Chief Operating Officer, Isotechnika Pharma Inc., +1-780-487-1600 ext. 225, +1-780-484-4105 (fax), laspeslet at isotechnika.com